PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 14, 2026Intestinal Research0 citationsOpen Access

Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI study

View Full Paper
WLWenjia LiuHGHong GuoTKTae Oh Kim

Key Points

  • The aim is to evaluate the efficacy and safety of subcutaneous guselkumab in East Asian participants with Crohn's disease.
  • Subgroup analysis from the Phase 3 GRAVITI study
  • Focused on moderately to severely active Crohn’s disease
  • Compared results with the global study outcomes
  • Efficacy and safety findings align with global study results
  • Subcutaneous guselkumab demonstrated effectiveness for Crohn’s disease
  • Safety profile found consistent across populations

Abstract

Efficacy and safety results of SC guselkumab in East Asian participants with moderately to severely active CD reflect findings from the global study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/699011032ccff479cfe57646https://doi.org/10.5217/ir.2025.00107
Ask AI
Helpful
Bookmark
Share
View Full Paper